- Category: HIV Treatment
- Published on Wednesday, 06 February 2013 00:00
- Written by Liz Highleyman
On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.
As reported last week, a study published in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes found that lersivirine (formerly UK-453,061) suppressed HIV viral load as well as efavirenz (Sustiva) in a 48-week trial, but with a different and generally better tolerated side effects profile.
However, according to this week's announcement sent to HIV treatment writersfrom ViiV Director of External Affairs Marc Meachem, "[a]fter much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class."
The decision was "not due to any safety concerns regarding the compound," the announcement stated, adding that, "ViiV Healthcare's goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that offer improvement over current options."
M Meachem, ViiV Healthcare. Update Status of Lersivirine Development Program. February 5, 2013.